Posted by Michael Wonder on 14 Dec 2022
Agilent Resolution ctDx First receives FDA approval as a liquid biopsy companion diagnostic test for advanced non-small-cell lung cancer
12 December 2022 - Agilent Technologies announced today that the US FDA has approved Agilent Resolution ctDx First as a companion diagnostic to identify advanced non-small-cell lung cancer patients with KRAS G12C mutations who may benefit from treatment with Krazati (adagrasib).
This is the first liquid biopsy NGS assay approved by the FDA as a companion diagnostic for the newly approved Krazati in advanced non-small-cell lung cancer and was developed in collaboration with Mirati Therapeutics.
